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ABSTRACT 
Objectives: Most first episode psychosis (FEP) outcome studies are based on patient 
samples enrolled through an informed consent procedure, which may induce important 
biases.  Our aim was to study the 18-month outcome of FEP in an epidemiological 
sample of patients treated at the Early Psychosis Prevention and Intervention Centre 
(EPPIC).  
 
Methods: The files of 661 FEP patients treated for up to 18 months between 1998 and 
2000 were assessed. Symptomatic remission was defined as receiving a score ≤ 3 on 
the Clinical Global Impressions (CGI) scales, and functional remission as concurrent 
fulfillment of occupation/employment and independent living. Predictors were analyzed 
using stepwise logistic regression models. 
 
Results: At endpoint, 63% of FEP patients had reached symptomatic remission and 
44% functional remission. Duration of untreated psychosis, baseline symptom intensity, 
time in service and decrease or remission of substance use, predicted both symptomatic 
and functional outcome. A history of suicide attempt or non-adherence to medication 
was linked to lower likelihood to reach symptomatic remission while pre-morbid GAF and 
employment at baseline were linked to functional outcome.  
 
Conclusions: The development of early intervention strategies should be pursued, in 
order both to provide treatment before symptoms reach a high intensity and to maintain 
social integration. Specific strategies need to promote engagement, facilitate adherence 
to medication and to create a framework where key issues such as substance abuse co-
morbidity can be addressed. 
 
Key words: First episode psychosis, outcome, functioning, symptoms, predictors, 
schizophrenia
1. INTRODUCTION 
While outcome studies conducted in the 80’s1-3 contradicted the idea that schizophrenia 
would inevitably lead to profound deterioration, this disorder is still considered with pes-
simism, on the basis of more recent studies published in the nineties which have shown 
that, whilst a minority of patients may experience recovery, a majority will display re-
peated relapses and progressive impairment4,5. These disillusioning results were largely 
based on samples selecting hospitalized, chronic or treatment non-responsive patients 
and therefore may not reflect the entire span of outcome for these disorders6,7. Research 
based on first episode psychosis (FEP) samples offer the possibility to study a wider 
range of patients, including those who do not relapse after recovery from the initial psy-
chotic episode and may lead to the identification of factors linked to poorer outcome that 
may be influenced by treatment adaptations.  
In the first decade of 2000, six “population-based” FEP short term outcome studies have 
been published6-11 and later reviewed by DeMaio et al12. Their results suggest that after 
one to two years of treatment, rates of symptomatic remission range from 36% to 74%6-
11 and rates of functional remission from 26% to 51%7,9,10 and rates of combined symp-
tomatic and functional remission from 17% to 19%9,10. Male gender, living in a developed 
country, family history of schizophrenia, poor premorbid functioning, lower education 
level, earlier age of onset, insidious onset, longer duration of prodromal phase (DPP), 
longer duration of untreated psychosis (DUP), higher degree of negative symptoms at 
baseline, comorbidity of substance use disorder (SUD), diagnosis of schizophrenia and 
treatment with conventional antipsychotics were all identified as significant predictors of 
poor outcome in one or more of these studies. 
A later wave of similar studies have either compared the impact of specialized programs 
with standard treatment13 or compared subgroup of patients on the basis of characteris-
tics of interest such as substance abuse14 or cognition15 for example. Finally, more re-
cent studies have focused on longer term outcome and on the maintenance of the im-
pact of early intervention programs16, showing that unless specialized treatment is con-
tinued, their short term benefits could be lost after a few years17.  
However, despite being referred to as “population-based”, most of these studies still suf-
fer, to a variable degree, from an important selection bias, patients being enrolled 
through an informed consent procedure. Reported refusal rates, ranging from 24%6 to 
42%9 suggesting that results of such research may not be relevant to the most challeng-
ing FEP patients, who are unlikely to accept prospective assessment, such as those with 
highest illness severity, highest rate of SUD and poorer engagement in treatment. This 
assumption is supported by Menezes et al.’s 18 literature review on outcome in FEP. 
Worse outcome was mainly linked to the epidemiological representativeness of the co-
hort, and there were major differences between epidemiologically-based and selected 
FEP samples in terms of readmission rate (56.1% vs. 33.2%), employment rate (24.2% 
vs. 49.9%), global functional outcome (mean Global Assessment of Functioning (GAF19); 
48.6 vs. 60.1) and overall favorable outcome (35.6% vs. 50.3%). In addition, representa-
tiveness of a FEP sample is improved if it stems from a center with a treatment mandate 
in a catchment area where an early psychosis community awareness campaign has 
been conducted, which leads to a higher FEP recognition rate20 and where there are no 
financial barriers for access to care.  
The First Episode Psychosis Outcome Study (FEPOS) cohort fulfills these conditions 
and is based on an audit of the files of all patients who were treated at the Early Psycho-
sis Prevention and Intervention Centre (EPPIC) between 1998 and 200021,. Considering 
the limitations of previous studies mentioned above and in the frame of conducting a 
long term outcome study of the FEPOS sample, we wanted to answer the following 
questions regarding short term outcome in this unique clinical sample: (i) What are the 
rates of symptomatic remission and functional recovery in an epidemiological cohort 
treated in a specialized FEP service?; and (ii) What are the key pre-morbid, baseline, 
and treatment predictors of poor outcome in such patients? 
 
2. METHODS 
2.1. Patients sample 
Details of study methodology and context have been published previously21,22. The initial 
sample comprised a population-based cohort of 786 FEP patients consecutively admit-
ted to EPPIC in Melbourne between 1998 and 200021,22. At the time of the study, EPPIC 
was mandated to treat all FEP patients aged 15-29 in the catchment area with little if any 
leakage to private psychiatrists; as such, the study sample represents a treated epide-
miological cohort. The files of 82 patients (10%) had been sent to other services at time 
of discharge and were not available for the study; these patients did not differ regarding 
diagnostic distribution and available demographic characteristics. Among 704 available 
files, 43 were excluded because of a non-psychotic diagnosis at endpoint. Data on 661 
patients were analyzed. The local ethics committee granted approval for this study. The 
data result from extraction of information from the files on the basis of a file audit per-
formed between 2001 and 2002 by two experienced psychiatrists (ML and PC) assessed 
patients’ medical files using a specifically designed file-audit tool (Early Psychosis File 
Questionnaire; EPFQ21). The EPFQ is a form where data extracted from the files can be 
recorded. It contains the following domains of assessment: demographic data, forensic 
history, past history of suicide attempts, family history of mental illness, past psychiatric 
history, exposure to traumatic and life events, drug and alcohol assessment schedule 
(type of substance, age of onset, current use or not), premorbid level of functioning, age 
at onset of prodrome and first psychotic episode, intensity of symptoms and functional 
level at baseline and at the time of discharge or disengagement on the basis of scales 
described below.  
 
 
2.2. Diagnostic assessment 
Clinical diagnoses at EPPIC are the consensus result of an intensive diagnostic and 
treatment process, first within the initial 6 weeks of admission by well-trained clinicians 
working in a specialized assessment and crisis assertive community treatment team, 
and then throughout the entire duration of treatment. Diagnoses for FEPOS were de-
rived according to Diagnostic and Statistical Manual of Mental Disorder, 4th edition 
(DSM-IV criteria)23 on the basis of information gathered from the medical file and their 
validity has been established as detailed elsewhere21.  
 
2.3. Pre-treatment, baseline and outcome characteristics 
(i) Pre-treatment characteristics: Premorbid functioning was assessed with the Global 
Assessment of Functioning Scale (GAF), as recommended by the Early Psychosis As-
sociation for the definition of prodromal patients at high risk for transition to psychosis24. 
Duration of untreated psychosis (DUP) was assessed by means of the DUP-scale25,26. 
Age at onset was defined as the age when first sustained positive psychotic symptoms 
occurred, according to the DUP-scale25,26, on the basis of a procedure detailed else-
where27. Past psychiatric diagnoses were also assessed according to DSM-IV criteria 
and past suicide attempts according to ICD-10 classification28. (ii) Baseline and outcome 
characteristics: Patients were assessed on the basis of file data collected at baseline 
and at the time of discharge (either at the end of 18 months of treatment or on the basis 
of the last file-entry if patients moved out of catchment area, disengaged or had died). 
Severity of illness at baseline and discharge was assessed with the Clinical Global Im-
pressions-Severity of Illness scale (CGI-S29) and the CGI-BP mania and CGI-BP de-
pression (CGI-BP30). CGI scales are based on global assessment of illness severity rat-
ed from 1to 7. CGI-S scores the global severity of the illness, taking all elements into 
account while CGI-BP allows the scoring of the mania and depression dimensions sepa-
rately. Level of functioning was rated on the GAF. Insight into illness was assessed on 
the basis of one item with three anchors ranging from absent to partial and full in-
sight21,22. Patients were rated as “working at entry” (having employment/occupation at 
entry) on the basis of the Modified Vocational Status Index (MVSI31) if they fulfilled fol-
lowing criteria: having a job (full-time or part-time) or being a student at school or univer-
sity for at least the previous 4 weeks. Patients were rated as “living independently” on 
the basis of the Modified Location Code Index (MLCI31) if they fulfilled the following crite-
ria: being head of household, living alone or with peers or living with family under mini-
mal supervision. “Medication non-adherence” was defined as failure to take medication 
for 1 week or longer over the entire treatment period at EPPIC in accordance with Rob-
inson et al 32. Patients were also classified within 3 groups according to the evolution of 
SUD during treatment period in the following three groups: (i) absence of SUD; (ii) de-
crease or stopping of SUD over treatment period; and (iii) persistence, increase or com-
mencement of SUD over period22. Inter-rater reliability (between ML and PC) was estab-
lished for CGI-S (ICC2,1=0.87), GAF (ICC2,1=0.88), and insight score (ICC2,1=0.89).  
 
2.4. Outcome definitions 
Symptom remission was defined as a score ≤ 3 on all three of the discharge CGI rating 
scales (CGI-S, CGI-BP mania, and CGI-BP depression), similar to Lambert et al33. Func-
tional recovery was defined as concurrent fulfillment of: (1) occupational/vocational sta-
tus as measured by the MVSI (i.e., paid or unpaid full- or part-time employment, being 
an active student in school or university, or head of household with employed partner 
(homemaker), or full- or part-time volunteer); and (2) independent living according to the 
MLCI (i.e., head of household, living alone, with partner, or with peers, and living with 
family with minimal supervision).  
 
2.5. Data analysis 
Descriptive statistics were used to describe the pre-treatment, service entry, and treat-
ment characteristics of the entire cohort. For scale data not conforming to the normal 
Gaussian distribution, logarithmic transformations (plus a constant such as one where 0 
was observed in the data) were employed. Untransformed data are used to describe 
sample characteristics whereas transformed data were used in the proceeding analyses.   
Preliminary analyses focused on determining which pre-treatment, service entry, and 
treatment variables were related to symptom remission and functional recovery. A series 
of sequential logistic regression models were conducted with remission or recovery 
(poor outcome as the reference category) serving as the dependent variable and the 
predictor of interest (e.g., gender or substance use) the independent variable in the 
model. As length of time in service varied from less than one week to 208 weeks, time in 
service was entered into the first step of the model. For symptom remission, it was also 
important to control for baseline symptoms, so CGI-S and CGI-BP scores at service en-
try were also included in the first step. For functional recovery, vocational/occupational 
and independent living statuses at service entry were also included in the first step. The 
predictor of interest was entered into the second step of the model. From these logistic 
regression analyses, adjusted odds ratios (OR; adjusting for time in service and baseline 
characteristics), the 95% of confidence intervals (CI) of the adjusted ORs, and the p val-
ues for Wald statistics (z), are reported. A variety of contrasts were used to derive OR 
for categorical variables (i.e., gender, diagnosis, insight at entry) including indicator and 
deviation contrasts. 
Variables identified in these preliminary analyses to be significant predictors of remission 
or recovery (at the p<.10 level) were entered into two separate stepwise logistic regres-
sion models with each of the outcome measures serving at the dependent variable. The 
purpose of these models was to determine whether there were different predictors of 
symptomatic remission and functional recovery. ORs, 95% CI of the OR, and the p val-
ues derived from the Wald statistics were reported for the significant predictors of remis-
sion or remission included in the final step of the models.    
We were also interested to determine a series of cut-off scores that would best demar-
cate the number of risk factors associated with poor symptom remission or poor func-
tional recovery. For each outcome type, the risk factors associated with outcome were 
identified from the stepwise logistic models. A total risk score was then derived.  Re-
ceiver operator curves (ROCs) were then used to determine the appropriate cut-off 
scores. Youden’s J statistic was used to determine the performance of the cut-off 
scores. Area under the curve (AUC) values of ≥0.90 were considered excellent, 0.80-
0.90 good, 0.70-0.80 fair, and <0.70 poor.   
 
3. RESULTS 
3.1 Sample Characteristics 
Patients’ average age was 22.0 years and the majority was male, with a history of expo-
sure to traumatic events and SUD co-morbidity (see Table 1); 14.3% had a history of 
suicide attempt, baseline CGI-S score revealed a marked severity of illness and insight 
at entry was poor. On average, time in contact with the service lasted 63.3 weeks. Near-
ly two thirds of patients were not fully adherent to medication and persistent SUD was 
common, observed in 61% of patients.  
====================== 
Please insert table 1 here! 
====================== 
 
 
3.2 Remission and recovery Rates 
Data on symptomatic remission at discharge was available in 655 patients. The mean 
CGI-S score at discharge for the total cohort was 3.0 (SD=1.3), 1.1 (SD=0.53) for CGI-
BP mania and 1.4 (SD=1.0) for CGI-BP depression. Data found in the file on functional 
recovery was considered reliable in only 556 patients. On the MVSI, 44.7% (n=255, 
N=571) were engaged in meaningful employment.  On the MLCI, 83.0% (n=463, N=558) 
were living independently with minimal supervision.  Using the remission and recovery 
criteria specified earlier, there were 62.9% (n=412, N=655) patients who had achieved 
symptom remission and 44.2% (n=246, N=556) who had achieved functional recovery at 
discharge.  These percentages were determined for symptom and functioning as dis-
crete variables. Just over a third of patients had achieved combined remission at dis-
charge (37.6%, n=209, N=556). 
 
 
====================== 
Please Insert Figure 1 here! 
====================== 
 
3.3 Predictors of outcome 
A number of variables were associated with the various aspects of outcome, while con-
trolling for time in service and baseline characteristics (see Table 2). Among pre-
treatment variables, number of years in school, premorbid functioning, and DUP were 
associated with both symptomatic remission and functional recovery. In addition, age of 
onset and history of suicide attempts were related to symptomatic remission. Regarding 
baseline variables, global CGI-S of symptoms and employment status were associated 
with both symptomatic remission and functional recovery. A diagnosis of bipolar I disor-
der or schizophreniform disorder was associated with better symptomatic remission as 
compared to a diagnosis of schizophrenia. In addition, severity of depression and mania 
on CGI-BP scales and SUD status were associated with symptomatic remission. Global 
functional and insight levels at baseline were associated with functional recovery. Final-
ly, duration of time in service, adherence to treatment and evolution of SUD over the 
treatment period were associated with both symptom remission and functional recovery.  
====================== 
Please insert table 2 here! 
====================== 
 
 
The above variables as well as those associated with the outcomes at a p<.10 level 
were included in two stepwise logistic regression models to determine, which variables 
best predicted symptomatic remission and functional recovery (see Table 3). Forward 
method using Wald criteria was used to determine the selection of variables in the mod-
el. Four variables were significantly associated with both symptoms remission and func-
tional recovery: DUP, Intensity of symptoms at baseline (CGI-S), time in service and 
SUD profile. Regarding the latter, decrease or interruption of SUD was associated with 
better outcome and maintenance or increase of SUD with poorer outcome. Additionally, 
symptom remission was associated with the absence of a past history of suicide attempt 
and adherence to medication during treatment, while functional recovery was associated 
with pre-morbid GAF and employment status at baseline.  
====================== 
Please insert table 3 here! 
====================== 
 
 
A risk score for poor symptomatic outcome was derived on the basis of DUP, past his-
tory of suicide attempt, CGI-S at entry, adherence to treatment and SUD profile during 
treatment.  In order to dichotomise DUP, we chose, on the basis of earlier work27, a cut-
off at 30 days. CGI-S score were collapsed into 2 categories (score of 5 or below and 
score of 6 or 7). Thus, on the basis of these variables, an individual could obtain a total 
symptomatic risk score ranging from 0 to 5, with 5 depicting greater number of risk fac-
tors. Figure 1 depicts the ROC curve for the symptom risk score against not achieving 
symptomatic remission. The AUC was 0.76 (95% CI 0.71-0.79) indicating fair discrimina-
tion. On the basis of Youden’s J index, a cut off of greater than or equal to 3 on the risk 
score was chosen.  The sensitivity for the cut-off score was 0.66, specificity 0.75, posi-
tive predictive value (PPV) of 0.61 and negative predictive value (NPV) of 0.79.  
For functional outcome, a risk score was based on premorbid GAF, DUP, CGI-S, em-
ployment at service entry and SUD profile over treatment period. Premorbid GAF was 
dichotomised into <70 and ≥70.  An individual could receive a risk score for functioning 
out of 5. The AUC was 0.73 (95% CI 0.68-0.76) which is considered fair. On the basis of 
Youden’s J, a cut off of greater than or equal to 3 on the risk score was chosen. The 
sensitivity of the cutoff was 0.58, specificity 0.76, PPV was 0.76 and NPV of 0.59.   
 
4. DISCUSSION 
This study is one of the largest FEP outcome studies, and one of the very few based on 
a true epidemiological sample of patients treated in a specialized early psychosis service 
where operationalized criteria were applied to define symptomatic and functional out-
come. Considering FEPOS allowed the assessment of all patients treated at EPPIC over 
a defined period of time, including those who would be likely to refuse to participate in 
prospective studies, our results are likely to be representative of the outcome of FEP 
patients treated in a specialized centre embedded in the public system of similar socio-
economic level. 
 
 4.1. Key findings 
Our data showed that after a period of up to 18 months of treatment, 63% of FEP pa-
tients had reached symptomatic remission and 44% functional recovery. These findings 
confirm that, in the early phase of psychosis, outcome is better than previously thought. 
Compared to other studies, rate of symptomatic remission in our sample is similar to 
findings from the TIPPS project6, but relatively higher than rates observed after 2 years 
by Petersen et al9 and Wundering et al10. Likewise, rate of functional remission was also 
higher in our sample than both Petersen et al9 and Wunderink et al10 reported. This may 
be due to various factors. First, contrary to these two studies, FEPOS includes bipolar I 
disorders and other affective psychoses besides schizophrenia, a sub-group of patients 
who had a better outcome. Second, outcome criteria applied in these studies may have 
been more restrictive. Finally, better outcome in our sample could also reflect the effect 
of treatment at a centre that has been specialised in early intervention for many years. In 
addition, these outcome figures confirm the marked discrepancy between symptomatic 
and functional outcome7,31, and highlight the importance to address this issue in the early 
phase of psychoses. Data from a recent randomized controlled trial showed that voca-
tional intervention adapted to FEP patients have a significant impact on likelihood to re-
turn to work34; this confirms pilot data from Killackey et al35 and suggests more effort 
should be made in this direction.  
While a number of variables were associated with the aspects of outcome we explored, 
a stepwise logistic regression procedure identified those with the most robust predictive 
validity. Four elements appear to determine both symptomatic and functional outcome: 
treatment delay, intensity of symptoms at baseline, evolution of co-morbid substance 
use over the treatment period and time in treatment. Despite convincing evidence of an 
association between longer DUP and poorer outcome27,36 , this issue is still a matter of 
controversy; in keeping with the litterature6,9,10,11, our results support to the idea that re-
duction of DUP may improve outcome and should therefore be a priority in early inter-
vention programs. Higher intensity of symptoms at baseline was linked to poorer out-
come, which is congruent with findings from Menzes et al7 and suggests that symptom 
reduction in the early recovery phase may be a pre-requisite for patient to benefit from 
other aspects of treatment. Repeated assessment of symptomatic remission should 
therefore be conducted regularly and specific approach be applied when symptoms per-
sist37. Expanding on previous results22, we found that patients who decreased or inter-
rupted SUD during the treatment period were significantly more likely to reach both 
symptomatic and functional remission, even when compared to patients who did not 
present this comorbidity at baseline. This latter observation, discussed in a previous pa-
per22 suggests that patients using substances may have better premorbid social compe-
tence and a form of illness where SUD may play a potentiating role; this confirms this 
potential for recovery should not be neglected and confirms the importance to address 
this issue in early psychosis patients. Finally, a longer engagement with the service was 
linked to a better outcome. Engagement and therapeutic alliance are closely inter-
connected, and there is now compelling evidence showing that the therapeutic relation-
ship is a significant predictor of clinical outcome across a number of disorders38-41. A 
shorter duration of treatment is likely to prevent such a relationship to establish, and to 
deprive patients from exposure to psychotherapeutic aspects of the treatment. Our re-
sults emphasize the importance to identify such patients early and to use an adapted 
approach, in order to facilitate their engagement41-43 and increase their chances of func-
tional remission. Finally, these results are in line with more recent outcome studies sug-
gesting that treatment should be pursued for sufficient time if short term benefits are to 
be maintained over time16,17.  
 
Symptom remission was predicted by two additional factors. First, in keeping with Malla 
et al44 and Petersen et al9, patients who were adherent to treatment were twice more 
likely to display symptom remission after 18 months. Second, patients who had suicide 
history of suicide attempts in the past were less likely to achieve symptoms remission; 
while this needs further exploration, our hypothesis is that occurrence of previous suicide 
attempt may be linked to other characteristics such as exposure to sexual abuse or co-
morbid borderline personality traits, which may explain persistence of symptoms that are 
globally assessed by the CGI-S scale.  
 
Finally, patients with a higher premorbid functional level and those who were employed 
or had a meaningful activity at baseline had a better functional outcome at the end of the 
treatment period. This confirms data from previous studies6,8,9 and suggests the effort to 
develop early intervention strategies that may prevent or delay development of psycho-
sis should be pursued, considering they may offer an opportunity to mitigate premorbid 
decline in functioning and risk of social marginalization.  
 
Globally, it is interesting to note that our study replicated the various outcome predictors 
that have been identified in previous studies that were based on informed consent pro-
cedure; although this would need to be replicated, it suggests that the informed consent 
procedure may not induce a major bias in study samples, which is reassuring. 
 
In an attempt to provide clinicians with elements predicting individual trajectories, we 
attempted to define cut-off scores that would best demarcate the number of risk factors 
associated with poor outcome. This analysis showed that symptom remission is unlikely 
to occur if a patient displays 3 or more of the following factors: DUP longer that 30 days, 
past history of suicide attempt, CGI≥6, poor adherence to treatment and increase or per-
sistence of SUD over the treatment period. Similarly, functional recovery is unlikely if a 
patient displays 3 or more of the following factors: DUP longer than 30 days, unemploy-
ment at baseline, pre-morbid GAF<70, CGI≥6 and increase or persistence of SUD over 
the treatment period. The validity of these predictive profiles need, however, to be vali-
dated prospectively. 
 
4.2 Limitations 
Some limitations should be kept in mind when interpreting the results. (1) Data was 
gathered retrospectively, and are based on case notes written by numerous clinicians 
whose inter-rater reliability could not be evaluated. Elements of patients’ past history as 
well as their symptoms may be under-reported by patients, unnoticed by clinicians or not 
transcribed in the files. Other factors that usually limit the validity of data extracted from 
medical record comprise: a lack of information due to multiplicity of treatment sites and 
multiplicity of files for a single patient; file assessment by raters lacking clinical experi-
ence; absence of strategies to limit inconsistencies between raters in data collection; or 
absence of strategies to assess validity of the data collected from the files. However, in 
the present study, files were assessed exclusively by two senior clinicians (PC & ML) 
who have extensive experience in treatment of early psychosis and have a thorough 
knowledge of the single site EPPIC program. Additionally, validity of the data as well as 
inter-rater reliability were assessed and proven satisfactory, as highlighted in the meth-
ods section. (2) The fact that 10% of the files were not available du to the fact that they 
had been sent to other services where patients continued to receive treatment after dis-
charge from EPPIC is also a limitation to the representativeness of the sample. (3) Un-
fortunately, data on functional outcome (location and vocation) was reliably recorded in 
the file for only 71% of the initial cohort, which limits the value of the results. It should 
also be mentioned that functional recovery was broadly defined, including for example 
part time unpaid job or living with friends. This definition may be considered over inclu-
sive, but the aim was to capture return to activity and ability to live in an environment not 
specifically designed for the care of psychiatric patients and is in line with the recovery 
concept where the definition of a fulfilling life doesn’t forcibly include paid job. (4) As 
mentioned in the methods section, outcome was based on file entries at 18 months or on 
the last file entry in case of disengagement or movement outside of catchment area, 
which explains the variability in treatment duration. While duration of treatment was 
taken into account in data analysis, this is likely to have nevertheless biased the results. 
(5) Finally, due to the retrospective nature of this study, ratings of symptom remission 
are based on CGI-S score, which only provides a very global reflection of symptom lev-
els; specifically, this scale doesn’t allow the distinction between positive and negative 
symptoms while the latter are an important driver of unfavorable trajectory. Assessment 
of symptom remission could not be done on the basis criteria published in the litera-
ture45; however, such criteria have been developed for schizophrenia and would not 
necessarily be adapted to patients with affective psychosis.  
 
4.3. Clinical implications and future research directions 
Considering these strengths and limitations, this study provides important information 
regarding outcome characteristics of a large epidemiological sample of FEP patients, 
and shows that while two thirds are in symptom remission after 18 months of treatment, 
60% fail to reach functional recovery.  We suggest that various strategies may contribute 
to improve these figures. First, the development of early intervention strategies should 
be pursued, not only in order to shorten DUP and to provide treatment before symptoms 
reach a high intensity, but also with the aim to maintain social and functional integration. 
Second, a good knowledge of the specific approaches that may promote engagement45 
is necessary when treating FEP patients, in order not only to facilitate their adherence to 
medication but also to allow sufficient time in treatment, in order to address key issues 
such as substance abuse co-morbidity. This study allowed us to examine the potentially 
modifiable risk factors that impact on the short-term outcomes of FEP patients. Im-
portantly, a study mapping the longer term illness trajectories and outcomes (over 15 
years) of this cohort is currently being undertaken and we will be able to determine 
whether the risk factors that influence short-term outcomes also impact on long-term 
illness course.  
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Table 1 
Description of patients’ demographic, premorbid, service entry, and treatment character-
istics for 661 patients with first episode psychosis 
Predictor variables  Statistic  Value for Total samplea
Pre‐treatment variables    
Age (years)  M (SD)  22.0 (3.4) 
Sex (% Male)  % (n)  65.8 (435) 
Years in school  M (SD)  10.5 (1.5) 
Pre‐morbid GAF  M (SD)  69.4 (10.6) 
Duration of untreated psychosis (in weeks)  M (SD)  36.4 (77.7) 
Mdn  8.7 
Age at onset (years)  M (SD)  21.3 (3.6) 
Exposure to traumatic event (% Yes)  % (n)  82.7 (544) 
Past history of suicide attempt (% Yes)  % (n)  14.3 (93) 
Past substance use disorder (%Yes)  % (n)  74.1 (490) 
Forensic history (%Yes)  % (n)  28.9 (187) 
Baseline variables    
Diagnosis at entry (%Yes)   
Schizophrenia   % (n)  22.0 (145) 
Schizophreniform disorder  % (n)  39.1 (258) 
Schizoaffective disorder  % (n)  6.1 (40) 
Bipolar I disorder  % (n)  18.9 (125) 
Other psychosis  % (n)  14.0 (92) 
Severity of symptoms at entry   
CGI‐S severity score  M (SD)  5.5 (0.8) 
CGI‐BP depression score  M (SD)  2.0 (1.6) 
CGI‐BP mania score  M (SD)  2.0 (1.8) 
Functional level at entry (%Yes)   
Employment/occupation  % (n)  48.0 (316) 
Independent living  % (n)  74.5 (487) 
Substance use disorder (SUD) (% Yes)  % (n)  61.4 (406) 
Insight at entry (%No)  % (n)  62.4 (410) 
Treatment variables    
Length of time in service (in weeks)  M (SD)  63.3 (34.2) 
Compliance with treatment (%No)  % (n)  60.6 (379) 
Substance use disorder (SUD) (% Yes)   
No SUD  % (n)  34.6 (229) 
Remitted SUD (decreased or stopped)  % (n)  25.3 (167) 
Persistent SUD (increased or no change)  % (n)  40.1 (265) 
a Percentages were based on non‐missing observations.  
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Table 2: Adjusted odds ratios from preliminary analyses depicting the relationships between pre-treatment, service 
entry and treatment characteristics and remission 
          
  Symptomatic remission   Functional remission 
Predictor OR a 95% CI 
p-
value 
  
OR b 95% CI 
p-
value 
Pre-treatment variables                   
Age (years) 1.03 0.98 1.08 .237 0.99 0.94 1.04 .728 
Sex (male) 0.81 0.57 1.16 .251  0.79 0.54 1.15 .218 
Years in school 1.14 1.02 1.28 .022  1.18 1.04 1.35 .013 
Pre-morbid GAF 1.04 1.02 1.06 <.001  1.04 1.02 1.06 <.001 
Duration of untreated psychosis (in weeks) d 0.51 0.39 0.66 <.001  0.56 0.43 0.74 <.001 
Age at onset (years) 1.06 1.02 1.11 .010 1.01 0.96 1.07 .638 
Exposure to traumatic event (%Yes) 0.97 0.62 1.50 .875 0.95 0.60 1.52 .832 
Past history of suicide attempt (%Yes) 0.43 0.27 0.70 .001 0.93 0.55 1.57 .771 
Past substance use disorder (%Yes) 0.72 0.48 1.07 .099 0.88 0.59 1.31 .521 
Forensic history (%Yes) 0.70 0.49 1.00 .052 0.75 0.49 0.14 .181 
Baseline variables                   
Diagnosis at entry   
Schizophrenia Reference category Reference category 
Schizophreniform disorder 1.57 1.09 2.24 .015 1.23 0.87 1.72 .238 
Schizoaffective disorder 0.77 0.42 1.4 .389 0.52 0.26 1.00 .051 
Bipolar I disorder 2.13 1.17 3.86 .013 1.45 0.96 2.21 .080 
MDD with psychotic features 0.78 0.33 1.85 .328 1.61 0.72 3.59 .246 
Other psychosis 1.01 0.62 1.65 .966 1.13 0.68 1.89 .635 
Severity of symptoms at entry   
CGI-S severity score 0.66 0.53 0.83 <.001 0.68 0.54 0.85 .001 
CGI-BP depression score 1.12 1.01 1.25 .037 1.09 0.97 1.22 .148 
CGI-BP mania score 1.26 1.14 1.40 <.001 1.01 0.91 1.12 .872 
Functional level at entry   
Employment/occupation (%Yes) 1.82 1.29 2.55 .001  3.99 2.77 5.75 <.001 
Independent living (%Yes) 1.26 0.87 1.84 .224  1.43 0.95 2.17 .090 
GAF 1.01 0.98 1.03 .701  1.03 1.01 1.05 .004 
Substance use at entry (%Yes) 0.69 0.49 0.98 .039 0.79 0.54 1.13 .197 
Insight at entry (%No) 0.85 0.58 1.25 .393  0.63 0.43 0.91 .015 
Treatment variables                 
Length of time in service 1.01 1.01 1.02 <.001  1.01 1.01 1.01 .014 
Compliance with treatment (%Yes) 3.37 2.29 4.94 <.001  1.51 1.03 2.22 .034 
Substance use disorder (SUD)   
No SUD Reference category  Reference category 
Remitted SUD (decreased or stopped) 2.51 1.93 3.25 <.001  1.65 1.27 2.14 <.001 
Persistent SUD (increased or no change) 0.24 0.18 0.32 <.001   0.44 0.32 0.60 <.001 
a Adjusted odds ratio controlling for time in service, and CGI-S and CGI-BP service entry scores 
b Adjusted odds ratio controlling for time in service, and working/studying and independent living status at service entry 
c Adjusted odds ratio controlling for time in service, and service entry symptom and functioning variables 
d Logarithmic transformation (plus constant) was applied to the variable due to extreme skewnesss 
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Table 3: Results (OR, 95% CI OR, and p value from Wald statistics) from two stepwise logistic regression (based 
on forward Wald criteria for selection of variables) models depicting the best predictors of symptomatic 
andfunctional ombined remission.  
 
               
  
Symptomatic remission 
(n=528) 
 Functional remission    
(n=459) 
Predictor OR 95% CI 
p-
value 
 
OR 95% CI 
p-
value 
Pre-treatment variables                  
Years in school 
Pre-morbid GAF 1.02 1.01 1.05 .041 
Duration of untreated psychosis (in days) d 0.51 0.38 0.69 <.001 0.53 0.39 0.72 <.001 
Age at onset (years) 
Past history of suicide attempt (%Yes) 0.52 0.30 0.90 .020 
Baseline variables                  
Diagnosis at entry         
Schizophrenia 
Schizophreniform disorder 
Schizoaffective disorder 
Bipolar I disorder 
MDD with psychotic features 
Other psychosis 
Severity of symptoms at entry 
CGI-S severity score 0.72 0.55 0.94 .016 0.63 0.48 0.82 .001 
CGI-BP depression score 
CGI-BP mania score 
Functional level at entry 
Employment/occupation (%Yes) 2.92 1.93 4.43 <.001 
GAF 
Substance use at entry (%Yes) 
Insight at entry (%No) 
Treatment variables                  
Length of time in service 1.01 1.01 1.02 .015 1.01 1.01 1.02 .004 
Adherence with treatment (%Yes) 0.42 0.27 0.65 <.001 
Substance use disorder (SUD) <.001 <.001 
No SUD Reference category 
Remitted SUD (decreased or stopped) 2.37 1.79 3.14 <.001 1.63 1.23 2.17 .001 
Persistent SUD (increased or no change) 0.27 0.20 0.37 <.001  0.53 0.38 0.75 <.001 
a Logarithmic transformation (plus constant) was applied to the variable due to extreme skew-
nesss 
Abbreviations: CGI-S = Clinical Global Impressions-Severity of Illness scale, GAF - Global Assessment 
of Functioning, SUD = substance use disorder 
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Figure 1. Receiver operating curve (ROC) for poor symptomatic and poor functional outcomes (based 
on DUP, past history of suicide attempt, CGI-S at entry, adherence to treatment and SUD profile during 
treatment).    
 
 
